MSB 1.41% $1.05 mesoblast limited

Ryoncil: ODAC/FDA Meeting Discussion, page-402

  1. 473 Posts.
    lightbulb Created with Sketch. 800
    https://hotcopper.com.au/data/attachments/2379/2379362-266845a8435ae25d5acd9988be6cf1f3.jpg
    Okay, lets see how the panel will discuss these points:

    Point 1-3: patients from 001 trial used the same lot of cells. thus, there is little variability of TNFR1 expression in the same lot of cells. the outcome (ie: responder vs non-responder) might be purely attributed to variability in patients and their immune system and disease severity/stage.

    Point 4: Significant was observed (as shown by SI) the optimized protocol produced better outcome. But importantly, TNFR1 expression level correlates with survival/better outcome.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.05
Change
-0.015(1.41%)
Mkt cap ! $1.198B
Open High Low Value Volume
$1.09 $1.09 $1.05 $4.232M 3.978M

Buyers (Bids)

No. Vol. Price($)
4 61694 $1.05
 

Sellers (Offers)

Price($) Vol. No.
$1.06 45910 3
View Market Depth
Last trade - 16.10pm 15/05/2024 (20 minute delay) ?
Last
$1.06
  Change
-0.015 ( 0.63 %)
Open High Low Volume
$1.09 $1.09 $1.05 969435
Last updated 15.59pm 15/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.